Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Andre P. Fay"'
Autor:
Danieli B. Guerra, Elisa M. N. Oliveira, Amanda R. Sonntag, Patricia Sbaraine, Andre P. Fay, Fernanda B. Morrone, Ricardo M. Papaléo
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract In this work, an intercomparison of sensitization effects produced by gold (GNP) and dextran-coated iron oxide (SPION-DX) nanoparticles in M059J and U87 human glioblastoma cells was performed using 6 MV-photons. Three variables were mapped:
Externí odkaz:
https://doaj.org/article/0c6cc2841f3348fd881508c1d996a4c4
Publikováno v:
Journal of Global Oncology, Vol 4, Pp 1-14 (2018)
Purpose: Health determinants vary according to geographic region and may affect the outcomes of patients with metastatic renal cell carcinoma (mRCC) treated during clinical trials of targeted therapy. Here, we investigate the overall survival (OS) of
Externí odkaz:
https://doaj.org/article/6caf3fd06480411caa68c6f15c0ace4a
Autor:
Gustavo Werutsky, Mahira Lopes, Rafaela Gomes de Jesus, Antonia Angeli Gazola, Rodrigo Azevedo Pellegrini, Taiane Francieli Rebelatto, Laura von Wallwitz Freitas, Ana Paula Heck, Arthur Ferreira da Silva, Matheus Füehr Rodrigues, Gustavo Gössling, Juliana Giacomazzi, Matheus Soares Rocha, Daniela Dornelles Rosa, Carlos Henrique Barrios, Eduardo Henrique Cronemberger, Geraldo Silva Queiroz, José Bines, Sérgio Daniel Simon, Andre Poisl Fay
Publikováno v:
Revista Brasileira de Ginecologia e Obstetrícia, Vol 46 (2024)
Abstract Objective To analyze marital outcomes, divorce or separation, and its association with demographic, socioeconomic, and clinicopathological factors among breast cancer (BC) survivors after 2-years of diagnosis. Methods We performed a retrospe
Externí odkaz:
https://doaj.org/article/c5bc6bb69ed942a692de074512500a80
Autor:
Toni K. Choueiri, Darren Feldman, Robert J. Motzer, Sabina Signoretti, Lauren C. Harshman, James J. Hsieh, Jae Lyun Lee, Sumanta K. Pal, JoAnn Hsu, Fabio A. Schutz, Andre P. Fay, Daniel Y. Heng, J. Connor Wells, Guillermo De Velasco, Daniel Castellano, Eliezer Van Allen, David A. Braun, Xiao X. Wei, Dylan J. Martini, Aly-Khan A. Lalani, Raphael Brandao, Abdallah Flaifel, Stephanie A.M. Wankowicz, Wanling Xie, Dominick Bossé, Rana R. McKay
Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors have shown activity in metastatic clear cell renal cell carcinoma (ccRCC). Data on the activity of these agents in patients with non–clear cell RCC (nccRCC) or patients with sarcomatoid/r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc7a3b136f17fc5d33e77f0d7330319b
https://doi.org/10.1158/2326-6066.c.6549214.v1
https://doi.org/10.1158/2326-6066.c.6549214.v1
Autor:
Toni K. Choueiri, Darren Feldman, Robert J. Motzer, Sabina Signoretti, Lauren C. Harshman, James J. Hsieh, Jae Lyun Lee, Sumanta K. Pal, JoAnn Hsu, Fabio A. Schutz, Andre P. Fay, Daniel Y. Heng, J. Connor Wells, Guillermo De Velasco, Daniel Castellano, Eliezer Van Allen, David A. Braun, Xiao X. Wei, Dylan J. Martini, Aly-Khan A. Lalani, Raphael Brandao, Abdallah Flaifel, Stephanie A.M. Wankowicz, Wanling Xie, Dominick Bossé, Rana R. McKay
Includes: Table 1S. Baseline patient and disease characteristics. Table 2S. Tumor mutation burden status. Table 3S. PDL1 expression data. Figure 1S. Overall survival for the total cohort.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::050a1b150ce3998dd89220d1a3afb6e9
https://doi.org/10.1158/2326-6066.22539886.v1
https://doi.org/10.1158/2326-6066.22539886.v1
Autor:
David J. Kwiatkowski, Toni K. Choueiri, Sabina Signoretti, Katherine M. Krajewski, Ronan Flippot, Pier Vitale Nuzzo, Sarah Abou Alaiwi, Kathryn D. Lasseter, Andre P. Fay, Aaron R. Thorner, Kathryn P. Gray, Lana Hamieh, Amin H. Nassar
We previously showed that alterations in mTOR pathway genes were correlated with response to rapalog therapy in metastatic renal cell carcinoma (mRCC), when the analysis focused on extremes of response. Herein, we expand on the prior cohort and exami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1b5eef3c307e851770a322f8842e6f0
https://doi.org/10.1158/1535-7163.c.6542307.v1
https://doi.org/10.1158/1535-7163.c.6542307.v1
Autor:
David J. Kwiatkowski, Toni K. Choueiri, Sabina Signoretti, Katherine M. Krajewski, Ronan Flippot, Pier Vitale Nuzzo, Sarah Abou Alaiwi, Kathryn D. Lasseter, Andre P. Fay, Aaron R. Thorner, Kathryn P. Gray, Lana Hamieh, Amin H. Nassar
Table S1. Clinical and molecular data sets, and statistical analyses for 109 RCC subjects treated with rapalogs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::008dc74fce4e65f645909c39d5b31a27
https://doi.org/10.1158/1535-7163.22519116.v1
https://doi.org/10.1158/1535-7163.22519116.v1
Autor:
Neeraj Agarwal, Arun Azad, Neal D Shore, Joan Carles, Andre P Fay, Curtis Dunshee, Lawrence Ivan Karsh, Maria Luisa Paccagnella, Nicola Di Santo, Mohamed Elmeliegy, Xun Lin, Akos Czibere, Karim Fizazi
Publikováno v:
Scientia
PARP inhibitor; Androgen receptor; Enzalutamide Inhibidor de PARP; Receptor d'andrògens; Enzalutamida Inhibidor de PARP; Receptor de andrógenos; Enzalutamida PARP inhibitors in combination with androgen receptor-targeted therapy have demonstrated p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c2bc7f7065b7a3673c5c385a9dcfdf4
https://doi.org/10.2217/fon-2021-0811
https://doi.org/10.2217/fon-2021-0811
Autor:
Neeraj Agarwal, Arun Azad, Neal D Shore, Joan Carles, Andre P Fay, Curtis Dunshee, Lawrence Ivan Karsh, Maria Luisa Paccagnella, Nicola Di Santo, Mohamed Elmeliegy, Xun Lin, Akos Czibere, Karim Fizazi
Publikováno v:
Scientia
What is this summary about? This summary describes the design of an ongoing research study (also known as a clinical trial) called TALAPRO-2. The TALAPRO-2 trial is testing the combination of two medicines called talazoparib and enzalutamide as a fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e0e9c5e934f747db4d0883c2cd400b8
https://pubmed.ncbi.nlm.nih.gov/35950899
https://pubmed.ncbi.nlm.nih.gov/35950899
Autor:
Fernando Sabino Marques Monteiro, Laura Freitas, Rafaela Gomes de Jesus, Bruno Hochhegger, Pedro Cavalcante, Gustavo do Vale Gomes, Andre P. Fay, Diego H. Roman, Vinicius K. Gonçalves, Juçara Motta Serafim Eliam
Publikováno v:
Prostate International
Prostate International, Vol 9, Iss 1, Pp 54-59 (2021)
Prostate International, Vol 9, Iss 1, Pp 54-59 (2021)
Background According to pathologico-clinical features, patients diagnosed with localized prostate cancer (PCa) are stratified into distinct risk groups (low-risk, intermediate-risk or high-risk). Data have demonstrated that 68Gallium-prostate-specifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1df6b7d949cfe6aa5595666da9c2cc00
https://doi.org/10.1016/j.prnil.2020.07.007
https://doi.org/10.1016/j.prnil.2020.07.007